Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ALGN
STRONG BUYFLAGAlign Technology, Inc. · Healthcare · United States · $12.0B · Avg Vol: $169M/d
Align Technology has Q78 M66 with an active buyback, but value at V46 is below the calibrated floor. Clear aligners at a full valuation, with the same discretionary-demand exposure as its Chinese peer earlier in this batch.
COMPANY DESCRIPTION
Align Technology is a global medical device company best known for its Invisalign system of clear aligners for orthodontic treatment, alongside its iTero intraoral scanners. The company holds a dominant market position in the clear aligner segment, protected by extensive intellectual property and a comprehensive ecosystem that includes treatment planning software and professional training. This strong brand recognition and innovative product portfolio establish a significant competitive moat in the dental aesthetics market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.7B | 3.9B | 4.0B | 4.0B | 2.6% | 4.1B | 4.2B | 4.4B | 4.0% |
| EPS | 4.62 | 5.82 | 5.63 | 5.66 | 7.0% | 5.89 | 6.12 | 6.66 | 8.5% |
| Shares | 77.3M | 75.1M | 73.8M | 71.4M | -7.6% | 71.6M | — | — | — |
| Debt | 126.9M | 126.6M | 119.3M | 114.4M | -3.4% | 116.0M | — | — | — |
| Equity | 3.6B | 3.6B | 3.9B | 4.0B | 4.0% | — | — | — | — |
| Op CF | 568.7M | 785.8M | 738.2M | 593.2M | 1.4% | 691.6M | — | — | — |
| Inv CF | -213.3M | -195.9M | -254.9M | -112.4M | — | — | — | — | — |
| Fin CF | -501.7M | -598.3M | -355.7M | -464.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ALGN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ALGN | Align Technology, Inc.(you) | $12.0B | 93 | STRONG BUY |
| SOLV | Solventum Corporation | $13.5B | 80 | BUY |
| RMD.AX | ResMed Inc. | $29.0B | 93 | STRONG BUY |
| BAX | Baxter International Inc. | $11.6B | 71 | BUY |
| NVST | Envista Holdings Corporation | $4.3B | 90 | STRONG BUY |
| ATR | AptarGroup, Inc. | $8.4B | 74 | BUY |
| BDX | Becton, Dickinson and Company | $43.1B | 90 | STRONG BUY |
| WST | West Pharmaceutical Services, Inc. | $23.1B | 77 | BUY |
| ICUI | ICU Medical, Inc. | $3.9B | 83 | STRONG BUY |
| MMSI | Merit Medical Systems, Inc. | $4.4B | 79 | BUY |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%